Results 31 to 40 of about 918 (92)

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

Cancer Medicine, Volume 13, Issue 2, January 2024.
Abstract RGD peptide can be found in cell adhesion and signaling proteins, such as fibronectin, vitronectin, and fibrinogen. RGD peptides' principal function is to facilitate cell adhesion by interacting with integrin receptors on the cell surface. They have been intensively researched for use in biotechnology and medicine, including incorporation into
Hossein Javid, Mahsa Akbari Oryani, Nastaran Rezagholinejad, Ali Esparham, Mahboubeh Tajaldini, Mehdi Karimi‐Shahri   +5 more
wiley   +1 more source

Safety and kinetic variation profile of 177Lu-DOTA-TATE uptake in Neuroendocrine Tumors

, 2017
Trabalho de Projeto do Mestrado Integrado em Medicina apresentado à Faculdade de ...
openaire   +1 more source

[¹⁷⁷Lu]Lu-DOTA-TATE tumour and organ time-activity curves: prediction from a single-time-point [⁶⁸Ga]Ga-DOTA-TATE PET/CT measurement. [PDF]

EJNMMI Phys
Vasić V, Gustafsson J, Yousefzadeh-Nowshahr E, Beer AJ, Sjögreen Gleisner K, Glatting G.   +5 more
europepmc   +1 more source

Morphological versus spherical cellular geometry models: impact on dose-response of CA20948 cells to ¹⁷⁷Lu- and ¹⁶¹Tb-labeled DOTA-TATE and DOTA-LM3. [PDF]

EJNMMI Phys
Spoormans K, Crabbé M, Struelens L, Koole M.   +3 more
europepmc   +1 more source

Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3. [PDF]

Pharmaceuticals (Basel)
Greifenstein L, Martin M, Stephan S, Eismant A, Kramer CS, Landvogt C, Mueller C, Rösch F, Baum RP.   +8 more
europepmc   +1 more source

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial. [PDF]

Front Endocrinol (Lausanne)
Kolodziej M, Opalinska M, Mikolajczak R, Hubalewska-Dydejczyk A, Dedecjus M, Kowalska A, Saracyn M, Garnuszek P, Cieszykowska I, Januszkiewicz-Caulier J, Dlugosinska J, Durma AD, Jozwik-Plebanek K, Mroz A, Janiak K, Gasior-Perczak D, Trofimiuk-Muldner M, Sowa-Staszczak A, Braziewicz J, Lenda-Tracz W, Kacperski K, Budzynska A, Kubik A, Pastusiak P, Chalewska W, Borkowska A, Cegla P, Walecka-Mazur A, Szczodry A, Kaminski G.   +29 more
europepmc   +1 more source

Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [¹⁷⁷Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer. [PDF]

Pharmaceutics
Zavvar TS, Santo G, Gruber L, Kronthaler A, Hagenbuchner J, Skvortsova I, Piro I, Steiger K, Martinovic V, Minasch D, Löffler-Ragg J, di Santo G, Virgolini IJ, von Guggenberg E.   +13 more
europepmc   +1 more source

First Real-World Evidence on the Safety and Effectiveness of Lutathera^TM for Treating Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Insights from Post-Marketing Surveillance. [PDF]

Cancers (Basel)
Kim YI, Suh HY, Kang Y, Cho H, Hyun SH, Song YS, Ha S, Kang KW.   +7 more
europepmc   +1 more source

Radioligand Therapy in Cancer Management: A Global Perspective. [PDF]

Cancers (Basel)
Ninatti G, Lee ST, Scott AM.
europepmc   +1 more source

Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals. [PDF]

EJNMMI Radiopharm Chem
Ntihabose CM, Handula M, Piet A, Beekman S, van Dalen L, Eskandari N, Aydogan A, Stuurman D, de Ridder C, Konijnenberg M, Seimbille Y, de Blois E.   +11 more
europepmc   +1 more source